Form 4: VolitionRx CEO Butera Acquires Shares Through RSU Vesting, Cancels Unvested Units

CEO Salvatore Thomas Butera of VolitionRx Ltd. acquired shares through the vesting of restricted stock units (RSUs) and had unvested units cancelled.

Summary

• On August 15, 2024, Salvatore Thomas Butera, CEO of Volition Veterinary (and officer of VolitionRx Ltd.), reported changes in beneficial ownership of VolitionRx Ltd. stock.
• Butera acquired 21,250 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.00.
• These RSUs were part of an award of 85,000 RSUs granted on September 28, 2023, under the company's 2015 Stock Incentive Plan.
• The vesting of these RSUs was contingent upon achieving certain corporate performance goals by December 31, 2023, and June 30, 2024, as well as time-based vesting.
• Certain performance goals were met, leading to the vesting of the 21,250 RSUs, which are now subject to a 3-year time-based vesting schedule.
• The remaining 27,625 RSUs that did not meet the performance goals were cancelled on August 15, 2024.
• Butera directly owns 252,000 shares and jointly owns 99,350 shares with his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of RSUs suggests some performance goals were met, but the cancellation of other RSUs indicates that not all goals were achieved. Overall, it's a routine filing reflecting standard executive compensation practices.

Positives

• The vesting of RSUs indicates that certain corporate performance goals were achieved, which could be seen as a positive sign for the company.

Negatives

• The cancellation of 27,625 RSUs suggests that some performance goals were not met, which could be viewed negatively.

Risks

• Future vesting of the acquired RSUs is subject to a 3-year time-based vesting schedule, meaning the executive must remain with the company to fully realize the benefit.
• The value of the acquired shares is subject to the market price of VolitionRx Ltd. stock, which can fluctuate.

Future Outlook

The reporting person will receive shares of common stock equal to the number of RSUs that have vested upon settlement, subject to the time-based vesting schedule.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting of RSUs is a common form of executive compensation.

Comparison to Industry Standards

• RSUs are a standard form of executive compensation across various industries, often used to align management's interests with those of shareholders.
• The specific vesting terms (performance-based and time-based) are tailored to the company's goals and executive retention strategy.
• Comparing the size of the RSU grant and vesting schedule to those of peer companies would provide a better understanding of the competitiveness of VolitionRx's compensation practices.

Stakeholder Impact

• The vesting of RSUs could have a minor dilutive effect on existing shareholders.
• The achievement of performance goals, as indicated by the RSU vesting, could positively impact shareholder value.

Next Steps

• The reporting person will receive shares of common stock upon the vesting of the RSUs according to the time-based vesting schedule.
• Future Form 4 filings will likely be made as additional RSUs vest or other transactions occur.

Key Dates